Related Experiment Videos
Combination treatment in hypertension: the VeraTran Study
1Cattedra di Medicina Interna and Centro di Fisiologia Clinica e Ipertensionean, Ospedale S. Gerardo, Monza, Italy.
American Journal of Hypertension
|July 1, 1997
Summary
Fixed-dose combination therapy for hypertension, combining verapamil slow release (SR) and trandolapril, effectively controls blood pressure over 24 hours. This approach improves treatment adherence and efficacy compared to monotherapy.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Management
Background:
- Combination therapy is increasingly used for hypertension when monotherapy is insufficient.
- Combining drugs can improve patient adherence and the overall benefit-risk ratio of treatment.
Purpose of the Study:
- To review the principles of effective antihypertensive combination therapy.
- To assess the efficacy of a fixed-dose combination of verapamil SR and trandolapril.
Main Methods:
- A multicenter, double-blind, parallel-group study (VeraTran Study) was conducted.
- The study evaluated the effects of an 8-week treatment with fixed-dose verapamil SR and trandolapril.
- Clinic and 24-hour ambulatory blood pressure were monitored.
Main Results:
- The fixed combination of verapamil SR and trandolapril demonstrated effective blood pressure control.
- Balanced blood pressure reduction was observed throughout the 24-hour period.
Conclusions:
- Fixed-dose combination of a calcium antagonist (verapamil SR) and an angiotensin-converting enzyme (ACE) inhibitor (trandolapril) provides effective 24-hour blood pressure management.
- This combination strategy is a valuable option for hypertension treatment.